{"title":"Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study.","authors":"Neal D Shore, Henry H Woo","doi":"10.1080/14796694.2025.2479331","DOIUrl":null,"url":null,"abstract":"<p><p>This podcast features two of the investigators from the international, randomized, phase 3 EMBARK trial (NCT02319837) in conversation. EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation therapy and enzalutamide monotherapy, as compared with androgen deprivation therapy alone, in patients with nonmetastatic castration-sensitive prostate cancer and biochemical recurrence at high risk for metastasis. In this podcast, the second in the EMBARK series, the speakers discuss the key efficacy and safety findings from the trial, consider some of the patient-reported outcomes and their implications for quality of life, and review some of the implications for clinical practice.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1151-1156"},"PeriodicalIF":3.0000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11999357/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2479331","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This podcast features two of the investigators from the international, randomized, phase 3 EMBARK trial (NCT02319837) in conversation. EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation therapy and enzalutamide monotherapy, as compared with androgen deprivation therapy alone, in patients with nonmetastatic castration-sensitive prostate cancer and biochemical recurrence at high risk for metastasis. In this podcast, the second in the EMBARK series, the speakers discuss the key efficacy and safety findings from the trial, consider some of the patient-reported outcomes and their implications for quality of life, and review some of the implications for clinical practice.
期刊介绍:
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.